Kisspeptin: what the IVF and brain studies in people actually found

Kisspeptin sits at the very top of the reproductive hormone chain, and unlike most peptides sold online it has been studied properly in people. In IVF, a single injection of kisspeptin-54 triggered egg maturation in 95% of women at high risk of a dangerous over-response, with no moderate or severe cases of that complication [8]. Those trials were small, came mostly from one research group at Imperial College London, and used a form of kisspeptin that is not the one usually sold. It is not an approved medicine anywhere.

What it is

Kisspeptins are a family of peptides cut from a single precursor protein made in the hypothalamus. The versions studied in people are kisspeptin-54, described by researchers as the major circulating form in humans [7], and kisspeptin-10, the shortest fragment with full activity [4]. Both end in the same ten amino acids; kisspeptin-10 is simply that shared tail [4].

Its importance was discovered through genetics. In 2003 two groups independently found that people with faulty copies of the kisspeptin receptor gene (then called GPR54) never went through puberty, because their hypothalamus failed to drive the reproductive axis [1,2]. Kisspeptin turned out to be the switch upstream of gonadotropin-releasing hormone (GnRH): kisspeptin stimulates GnRH neurons, GnRH stimulates the pituitary to release LH and FSH, and those drive the testes and ovaries.

That position is what makes it interesting as a drug. Rather than replacing LH, as hCG does, or forcing the pituitary directly with GnRH, kisspeptin prompts the brain’s own GnRH release, which in theory keeps the body’s feedback controls in play.

The human evidence

Healthy men

The first human study gave six healthy men a 90-minute intravenous infusion of kisspeptin-54 or saline in a double-blind crossover design [3]. LH rose from an average of 4.2 to 10.8 U/L, with smaller rises in FSH and testosterone, and kisspeptin-54 had a half-life of about 28 minutes [3].

Kisspeptin-10 was tested in healthy men in Edinburgh in 2011 [4]. An intravenous bolus raised LH within 30 minutes, from 4.1 to 12.4 IU/L at the best dose (1 mcg/kg), but a higher dose produced a smaller response. A continuous infusion over 22.5 hours raised testosterone from 16.6 to 24.0 nmol/L and increased the frequency of LH pulses [4]. These were tiny studies (four to six men per arm) designed to map the physiology, not to treat anything.

Women with hypothalamic amenorrhoea

Hypothalamic amenorrhoea, where periods stop because the brain’s signal to the pituitary falters, is an obvious target [6]. The results show the central problem with kisspeptin as a treatment: the body adapts to it.

Given twice daily, kisspeptin-54 lost its effect: the FSH response had nearly vanished by day two [5]. Twice-weekly dosing caused only partial desensitisation, and after eight weeks, reproductive hormone levels were higher than with saline, with no adverse effects reported [5]. In a later study, five women with the condition each received a range of continuous intravenous doses; the best dose for each woman tripled the number of LH pulses over eight hours, but that best dose differed from woman to woman [6]. None of these studies tested whether kisspeptin restores periods or fertility in this group, and they were not designed to.

IVF: the most developed use

In IVF, women receive drugs to grow many follicles, then a “trigger” injection to mature the eggs before collection. The main risk of this step is ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening over-response [8]. Kisspeptin was tested as a trigger because it releases the body’s own LH in a surge lasting roughly 12 to 14 hours [9], which the researchers hoped would be enough to mature eggs without over-stimulating the ovaries.

The first study gave 53 women a single injection of kisspeptin-54 at one of four doses [7]. Eggs matured at every dose, 92% of women had embryos transferred, and 12 of 53 (23%) had a clinical pregnancy [7]. There was no comparison group.

The key trial then focused on 60 women at high risk of OHSS [8].

Across doses, clinical pregnancy was 53% and live birth 45% per transfer, and no woman developed moderate, severe or critical OHSS [8]. The randomisation was between kisspeptin doses, not against hCG or another trigger, so the trial cannot say kisspeptin is better than the alternatives.

A follow-up placebo-controlled trial in 62 high-risk women tested a second kisspeptin dose ten hours after the first [9]. More women reached the target egg yield with two doses (71% vs 45%), and ovarian over-response or moderate OHSS affected one woman on a single dose and none on two [9]. The authors themselves called for head-to-head comparisons with established triggers [9].

The brain

In 29 healthy young men, kisspeptin infusion increased activity in limbic brain areas in response to sexual and couple-bonding images on functional MRI, and reduced negative mood scores compared with placebo [10]. It is an intriguing single study and the source of much of kisspeptin’s online reputation as a libido peptide. It measured brain scans and questionnaires in a lab, not sexual function in daily life.

A drug version is in development

Native kisspeptin-54 has a half-life of under half an hour [3]. A synthetic kisspeptin receptor agonist, MVT-602, was compared with kisspeptin-54 in nine healthy women, six with polycystic ovary syndrome and six with hypothalamic amenorrhoea [11]. In the healthy women it produced an LH rise of similar height, but it peaked much later (21.4 vs 4.7 hours) and gave roughly four times the total LH exposure. Responses in women with polycystic ovary syndrome looked like those in healthy women, while in hypothalamic amenorrhoea the LH rise came earlier [11]. These were single-dose studies in 21 women, so they establish how the drug behaves, not whether it treats anything. This is the direction a licensed product would most likely take, and it underlines that the peptide vials sold online are not what the clinical programme is developing.

Safety and side effects

The published human studies involved short courses under close supervision. None reported serious harm in its summary, one explicitly reported no adverse effects over eight weeks [5], and the IVF trials were designed specifically to avoid OHSS [8,9]. That is reassuring but limited: the total number of people exposed is in the low hundreds, almost all from one group, and follow-up was short.

Two practical cautions. First, repeated dosing causes the reproductive axis to stop responding, which is the opposite of what someone taking it to raise testosterone would want [5]. Second, most kisspeptin sold for research use is kisspeptin-10, whose human data are one small physiology study in men [4]. The FDA keeps kisspeptin-10 on its list of substances that may pose significant safety risks in compounding, citing possible immune reactions, impurities and a lack of safety data for the proposed routes [12].

Legal and regulatory status

• US: not approved by the FDA. Kisspeptin-10 is in category 2 of the FDA’s interim compounding policy (503A), the group of bulk substances the agency says may present significant safety risks [12].
• UK: not licensed as a medicine; its IVF use has been within research trials.
• Sport: “kisspeptin and its agonist analogues” are prohibited at all times for male athletes, under S2.2.1 of the 2026 WADA Prohibited List [13].

What we still don’t know

• Whether kisspeptin triggers are as good as, or safer than, current IVF triggers in a head-to-head randomised trial.
• Whether any schedule can restore periods and fertility in hypothalamic amenorrhoea without the body becoming tolerant to it.
• What kisspeptin-10 injections under the skin do over weeks, which is how it is actually used outside trials.
• Whether the brain effects on mood and sexual response translate into any real-world benefit.
• How kisspeptin affects the brain in women. The imaging study discussed above enrolled only young heterosexual men [10].
• Whether the findings hold up outside the single research group that produced most of them.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols